Inhibitors of APOL1 and methods of using same

US12421249B2 · kind B2 · utility

Assignee

• Vertex Pharmaceuticals Incorporated · US

Inventors

• Jun Myun Ahn · Waltham, US
• Samantha ANGLE · Cambridge, US
• Michael Aaron Brodney · East Lyme, US
• Jingrong Cao · Newton, US
• John Cochran · North Andover, US
• Jon Come · Cambridge, US
• Leslie Dakin · Waltham, US
• Elena Dolgikh · Boston, US
• Brad D. Maxwell · Holliston, US
• Suganthini S. Nanthakumar · Newton, US
• Hardwin O′Dowd · Cambridge, US
• Jessica Howard Olsen · Brookline, US
• Timothy J. Senter · Arlington, US
• Akira Shimizu · Kyoto, JP
• Steven David STONE · Quincy, US
• Haoxuan Wang · Thousand Oaks, US

Key dates

• Filing date: Nov 8, 2023
• Grant date: Sep 23, 2025
• Expiry date: Nov 8, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The disclosure provides at least one entity chosen from compounds of Formula I, a tautomer thereof, a deuterated derivative of that compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).